This page is part of the Genetic Reporting Implementation Guide (v3.0.0-ballot: STU 3 Ballot 1) based on FHIR (HL7® FHIR® Standard) R4. The current version which supersedes this version is 2.0.0. For a full list of available versions, see the Directory of published versions
Generated Narrative: Observation
Resource Observation "TMB-therapuDrug"
Profile: Therapeutic Implication
status: final
category: Laboratory (Observation Category Codes#laboratory), Genetics (diagnosticServiceSectionId#GE)
code: Therapeutic Implication (To Be Determined Codes#therapeutic-implication)
subject: Patient/somaticPatient " HAMSBURG"
effective: 2023-02-01
performer: Practitioner/pathologistPractitioner " DOLIN"
derivedFrom: Observation/TMBExample
component
code: Therapeutic Implication (To Be Determined Codes#therapeutic-implication)
value: cancer sensitive to pembrolizumab (LOINC#LA6677-4 "Responsive")
component
code: Associated phenotype (LOINC#81259-4)
value: Non-small cell lung cancer (SNOMED CT#254637007 "Non-small cell lung cancer (disorder)")
component
code: Medication assessed (LOINC#51963-7)
value: Pembrolizumab ()
component
code: Conclusion Text (To Be Determined Codes#conclusion-string)
value: Non-small cell lung cancer with high TMB is sensitive to pembrolizumab